Precision Medicine in Oncology® | Specialty

Dr. Papadimitrakopoulou on Benefits of Liquid Biopsy Versus Standard Tissue in Lung Cancer

July 16th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the benefits of liquid biopsy compared with standard tissue in lung cancer.

Expert Highlights Need for Widespread Liquid Biopsy Use in Lung Cancer Treatment

July 15th 2019

Alain Borczuk, MD, discusses the recent advancements in lung cancer treatment, the evolving field, and the future potential for liquid biopsies.

Blood-Based Markers Key to Precision Medicine Approach in Breast Cancer

July 9th 2019

Mark E. Burkard, MD, PhD, discussed the significance of utilizing markers in the blood and highlighted emerging actionable mutations in breast cancer.

Genome Sequencing Studies Shake Up Views on the Cancer Mutation Landscape

July 2nd 2019

Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

Genomic Profiling Confirms MAPK/ERK Gene Alterations in Metastatic Prostate Cancer

June 27th 2019

MAPK/ERK gene alterations, primarily receptor tyrosine kinases, BRAF, and CDK4/6 amplifications, were found to be present in more than half of patients with heavily pretreated metastatic prostate cancer.

Dr. Papadimitrakopoulou on Distinguishing Features of the Guardant360 Assay in Lung Cancer

June 19th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses distinguishing features of the Guardant360 assay in non–small cell lung cancer (NSCLC).

Entrectinib Breaks Through With Japanese Approval for NTRK-Positive Tumors

June 18th 2019

Entrectinib received its first regulatory approval, as Japan’s Ministry of Health, Labour and Welfare has approved the drug for the treatment of adult and pediatric patients with NTRK fusion–positive, advanced recurrent solid tumors.

Evolutions in the Treatment of EGFR-Mutated NSCLC

June 4th 2019

Sequencing With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Second- and Third-Generation TKIs in EGFR-Mutated NSCLC

June 4th 2019

Treating With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Resistance to Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

June 4th 2019

Expert Shares Advantages, Challenges With Liquid Biopsies in Cancer Care

May 23rd 2019

Geoffrey Oxnard, MD, discusses testing error underlying liquid biopsy discordance, steps clinicians can take to optimize liquid biopsy, and where he sees this evolving in the treatment landscape for patients with cancer.

TLR Agonists Emerge as Potential New Partner for Checkpoint Inhibitors

May 15th 2019

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.

Dr. Papadimitrakopoulou on the Utility of Liquid Biopsies in NSCLC

May 11th 2019

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, discusses the utility of liquid biopsies in non–small cell lung cancer (NSCLC).

Genomic Assays Continue to Individualize Treatment for HR+ Breast Cancer

May 7th 2019

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

Role of Liquid Biopsies Still Needs Refining in Breast Cancer

April 25th 2019

Aditya Bardia, MD, MPH, discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.

Precision Medicine in Oncology: Overcoming Obstacles

April 19th 2019

Genomic Profiling in Solid Tumor Malignancies: Challenges

April 19th 2019